Brief introduction of Harbin Pharmaceutical Co., Ltd.

The predecessor of the company is Harbin Pharmaceutical Group Co., Ltd. Since its establishment, the company has achieved the goal of catching up with and surpassing the domestic advanced level in a relatively short period of time. At present, the company's leading products, such as penicillin sodium powder injection, ampicillin, cephalosporin IV, ginseng royal jelly and Shuanghuanglian powder injection, rank in the forefront of similar domestic enterprises, and more than 70 products are exported to more than 40 countries around the world. At present, the company has mastered the world-advanced antibiotic "three mother nuclei" production technology and a number of high-tech bioengineering products, laying a solid foundation for achieving the goal of catching up with and surpassing the international advanced level. 1993 became the first listed company in Heilongjiang province and the national pharmaceutical industry, and 1994 was rated as a national super-large enterprise.

Harbin Pharmaceutical Group Co., Ltd. is a large-scale enterprise integrating science, industry and trade. Now it has 1 listed subsidiaries and 13 wholly-owned subsidiaries. The group has 20,654,38+0,000 employees, including 4,760 professional technicians, accounting for 23.8% of the total employees. Group * * * produces six series, more than 20 dosage forms and 1000 varieties, including western medicine and traditional Chinese medicine preparations, western medicine bulk drugs, traditional Chinese medicine powder injections, bioengineering drugs and nourishing health products, among which the production and sales of leading products such as cefotaxime sodium, cephalosporin sodium and Shuanghuanglian powder injections rank first in China, and the production and sales of penicillin sodium powder injections rank second in China. In 2000, the total industrial output value was 6.8 billion yuan, the industrial added value was 654.38+0.24 billion yuan, the operating income was 6.65 billion yuan, and the profits and taxes were 654.38+0 billion yuan, increasing by 56%, 65.438+03%, 44% and 84% respectively over the same period of last year, achieving rapid leap-forward development for three consecutive years. The gross industrial output value and operating income of the Group rank first in the same industry in China.

Harbin Pharmaceutical Group Co., Ltd., which is controlled by the group, is the first listed company in the national pharmaceutical industry, and 1996 has been designated as one of the national key contact enterprises. 1997 was approved by the State Council as a pilot unit of 120 large enterprises.